The emerging therapeutic role of RNA interference in disorders of the central nervous system

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 450-454

  Dessy, A ^a   Gorman, J M ^b  

^a MIDDLEBURY COLLEGE   (United States)

^b Univ S Carolina Sch Med Vice P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA7 INTEGRIN; LIPOSOME; MESSENGER RNA; MICRORNA; PROTEIN; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; GENE SILENCING; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SPINOCEREBELLAR DEGENERATION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMANS; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 79951812512     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.312     Document Type: Review

References (24)

1. Rossbach, M. Small non-coding RNAs as novel therapeutics. Curr. Mol. Med. 10, 361-368 (2010).
2. Jagannath, A. & Wood, M. RNA interference based gene therapy for neurological disease. Brief. Funct. Genomic. Proteomic. 6, 40-49 (2007).
3. Nelson, P.T., Wang, W.X. & Rajeev, B.W. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 18, 130-138 (2008).
4. Gonzalez-Alegre, P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol. Ther. 114, 34-55 (2007).
5. Bak, M. et al. MicroRNA expression in the adult mouse central nervous system. RNA 14, 432-444 (2008).
6. Liu, Z., Sall, A. & Yang, D. MicroRNA: An emerging therapeutic target and intervention tool. Int. J. Mol. Sci. 9, 978-999 (2008).
7. Diamond, P.F. In vitro nucleic acid transfection methods. Genetic Engineering and Biotechnology News. 〈http://www.genengnews.com/ transfection/invitro.htm〉 (2007).
8. Schwartz, E.I. Potential application of RNAi for understanding and therapy of neurodegenerative diseases. Front. Biosci. 14, 297-320 (2009).
9. Vaishnaw, A.K. et al. A status report on RNAi therapeutics. Silence 1, 14 (2010).
10. Davis, M.E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
11. System Biosciences. Interferon Response Detection Kit for validation of siRNA experiments. 〈http://www.systembio.com/downloads/Manual-IRDkit-v4. pdf〈 (2006).
12. Boudreau, R.L. & Davidson, B.L. RNAi therapeutics for CNS disorders. Brain Res. 1338, 112-121 (2010).
13. Manjunath, N. & Dykxhoorn, D.M. Advances in synthetic siRNA delivery. Discov. Med. 9, 418-430 (2010).
14. Martineau, H.M. & Pyrah, I.T. Review of the application of RNA interference technology in the pharmaceutical industry. Toxicol. Pathol. 35, 327-336 (2007).
15. Prakash, S., Malhotra, M. & Rengaswamy, V. Nonviral siRNA delivery for gene silencing in neurodegenerative diseases. Methods Mol. Biol. 623, 211-229 (2010).
16. Sethi, P. & Lukiw, W.J. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci. Lett. 459, 100-104 (2009).
17. Lukiw, W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18, 297-300 (2007).
18. Konopka, W. et al. MicroRNA loss enhances learning and memory in mice. J. Neurosci. 30, 14835-14842 (2010).
19. Gehrke, S., Imai, Y., Sokol, N. & Lu, B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641 (2010).
20. Hatterer, J.A., Herbert, J., Hidaka, C., Roose, S.P. & Gorman, J.M. CSF transthyretin in patients with depression. Am. J. Psychiatry 150, 813-815 (1993).
21. Sullivan, G.M., Mann, J.J., Oquendo, M.A., Lo, E.S., Cooper, T.B. & Gorman, J.M. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol. Psychiatry 60, 500-506 (2006).
22. Kim, A.H. et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr. Res. 124, 183-191 (2010).
23. Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.M. & Kellermann, O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329, 1537-1541 (2010).
24. He, Y., Yang, C., Kirkmire, C.M. & Wang, Z.J. Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor. J. Neurosci. 30, 10251-10258 (2010).